AI Drug Discovery & Development Solution

Solving the AIDD validation bottleneck,
closing the gap to pre-clinical development

Artificial intelligence is transforming antibody discovery, but success depends on more than generating large numbers of candidates. As AI increasingly produces molecules with novel and non-natural architectures, rapid validation and early developability assessment have become critical to identifying molecules with the optimal balance of functionality, manufacturability, and clinical potential.

At ProBio, we bridge this gap by combining over 20 years of antibody discovery expertise with integrated validation and developability strategies. Through customized screening cascades and our PrepCMC™ platform, we evaluate functional performance, biophysical properties, and CMC readiness in parallel, enabling earlier risk reduction, faster candidate selection, and accelerated progression to IND-enabling studies.

By incorporating CMC developability assessment during late discovery and advancing key development activities ahead of traditional timelines, ProBio helps clients identify the right candidate with greater confidence and achieve toxicology drug substance production in as little as 4.5 months, even for complex molecules and high-concentration formulations.

Contact us

From AI Candidates to IND Readiness

• Smarter Screening for Better Candidates

  Move beyond high-volume testing to rapidly identify molecules with the greatest chance of success.

• Validation Backed By Real Drug Discovery Expertise

  Identify true functional
  leads early.

• From Better Candidates to Faster IND Readiness

  Optimize PCC selection with early CMC confidence.

ProPath™ AI Drug Discovery

The path between AI design and therapeutic reality

• Integrated Platform

  • Expression to PK/Tox, all in one workflow
  • Seamless program progression
  • Zero handoff friction, faster decisions

• Fast & High-Throughput

  • 10-day turnaround from gene to data
  • Automated high-throughput screening
  • Hundreds of samples processed daily

• AI-Ready Data

  • Customized, AI-ready data outputs
  • Flexible reporting formats
  • Optimized for model training

• Proven Discovery Expertise

  • Functionality and developability screening
  • Established assays and animal models

• 20+

  Years of deep expertise in biologics discovery

• 2500+

  Projects in therapeutic antibody

• 20+

  Projects in the clinical phase and marketed

4 Months From AI sequence to Pre-Tox Study

PrepCMC™ + ExpressCMC™

From transfection to Tox DS ready in as fast as 4.5 months

PrepCMC™ Fast Sample Preparation

• Uses the same host cell line and vector system as formal CMC
• Generates representative materials aligned with CMC specifications
• Ensures consistency in critical quality attributes (CQAs)

PrepCMC™ Developability Study

• Select the optimal CMC candidate using representative materials
• Identify development risks and key process parameters early
• De-risk and accelerate formal CMC development

ExpressCMC™ with PrepCMC™

• Advance process development earlier than conventional timelines
• Deliver Tox-ready drug substance in as little as 4.5 months from transfection
• Enables rapid progression for complex molecules and high-concentration formulations

mAb & low-concentration formulation

Non-mAb & high-concentration formulation (≥ 100mg/ml)

Case Study

High-Throughput Functional Screening Accelerates Discovery of High-Quality Bispecific Antibody Leads

Out of over 400 expressed bispecific constructs screened by FACS within three days, target A yielded 6 weak dual binders (n=176) and target B yielded 12 (n=193). In the nonspecific binding assay, 59 out of 336 hits registered below the BMK cutoff.

ProBio's integrated high-throughput screening platform enables rapid functional validation of large bispecific antibody libraries, helping AI-driven and conventional discovery programs quickly identify high-quality lead candidates. In this study, more than 400 expressed bispecific constructs were screened using a streamlined FACS-based workflow, progressing from antibody expression to data delivery within days.

The platform successfully identified target-specific dual binders against two antigens, while simultaneously assessing nonspecific binding liabilities to improve candidate quality. By combining automated expression, functional screening, and early developability assessment in a single workflow, ProBio helps clients reduce false positives, prioritize the most promising candidates earlier, and accelerate progression toward lead optimization and IND-enabling development.